Alpha-synuclein blocks neuronal protein transport, impairing waste recycling in Parkinson's

Parkinson’s disease, a progressive neurodegenerative disorder, now affects more than 10 million people worldwide. The hallmark of the condition is the accumulation of abnormal clumps of the protein alpha‑synuclein inside brain cells, a process that is believed to drive the disease’s motor and non‑motor symptoms.

Scientists have long studied these toxic protein aggregates to determine how they disrupt neuronal function and lead to cell death. While the presence of alpha‑synuclein inclusions has been confirmed in the brains of patients, the precise mechanisms by which they interfere with cellular processes—such as protein degradation, mitochondrial function, and synaptic transmission—remain unclear. Ongoing research aims to map the cascade of events from protein misfolding to neuronal loss, with the goal of identifying therapeutic targets that could halt or reverse the disease’s progression.

Despite significant advances in understanding Parkinson’s pathology, the exact link between alpha‑synuclein aggregation and neuronal demise is still elusive. Continued investigation into these mechanisms is essential for developing effective treatments and improving outcomes for the millions affected by this debilitating disease.